Nut Supplementation in Inflammatory Bowel Disease: A Proof-of-Concept Study of Gut Microbiome and Metabolome Effects
Key facts
- Who runs it
- Sheba Medical Center
- Where
- Israel1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 27 Feb 2025
- Ended
- 25 Sept 2025
- Type of study
- Interventional
- Treatments tested
- Mixed Nut Blend
- Record updated
- 17 November 2026
Who can take part
- Age
- 10 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients with Crohn's disease or ulcerative colitis in clinical remission, as determined by the treating physician
- Non-IBD volunteers (controls)
- Willingness and ability to provide written informed consent (and parental/guardian consent for minors)
Who cannot take part
- Active Crohn's disease or ulcerative colitis
- Known nut allergy
- Systemic antibiotic use within 4 weeks preceding enrollment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
People with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, often continue to experience disruptions in the gut microbiome and metabolism even when their disease is in clinical remission on biologic therapy. These persistent gut-level changes may contribute to disease flares over time.
Read full original descriptionShow less
Nuts are nutrient-dense foods rich in unsaturated fats, fiber, minerals, and polyphenols, and have been shown to support gut health in general and cardiometabolic populations. However, their specific effects on the gut microbiome and metabolome in people with IBD in remission have not been examined.
This proof-of-concept study investigated whether short-term, daily consumption of a standardized mixed nut blend (almonds, walnuts, and pecans) shifts the gut microbiome and metabolic signals of people with IBD toward a healthier, control-like profile.
Sixty participants: 21 healthy controls, 19 participants with Crohn's disease in remission, and 20 participants with ulcerative colitis in remission, underwent a 3-day nut-avoidance washout, followed by 10 days of consuming 30 g/day of a mixed nut blend. Fecal samples were collected on days -3, 0, 5, and 10 and analyzed for microbiome composition (16S rRNA sequencing) and metabolite profiles (untargeted LC-MS metabolomics). Participants also completed a food frequency questionnaire and a daily adherence survey.
The study aimed to characterize how a defined, single food item influences gut health signals in IBD remission, providing a foundation for larger, longer-term dietary interventions.
The group in the trial
- Mixed Nut SupplementationTreatment being tested
All participants received a defined mixed nut blend consisting of equal weights of raw almonds, walnuts, and pecans (10 g of each per daily portion, 30 g total) for 10 consecutive days, following a 3-day nut-avoidance washout period. Portions were pre-weighed, homogenized, sealed in dedicated single-use bags labeled with the intervention day, and distributed to each participant in a coded box of 10 bags.
Treatment: Mixed Nut Blend
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Simple Nut Supplementation Induces Positive Gut Metabolic Signals in Patients With Inflammatory Bowel Disease
- Record updated
- 17 November 2026